Consultant Psychiatrist, 1202, Sector 32-B, Chandigarh - 160 030.
Indian J Psychiatry. 2004 Oct;46(4):319-23.
Risperidone and olanzapine in treatment of psychiatric patients can provoke a plethora of tardive dyskinesias which pose problems for them. This clinical problem requires the urgent attention of mental health professionals. Hence a comprehensive research of Medline and related literature was undertaken from 1996 till August 2004. The published twenty two cases of risperidone (N=12) or olanzapine (N=10) induced tardive dyskinesia were critically reviewed and an attempt is being made to clarify the various issues associated with them. In these reports majority of patients were in younger age group, females and the interval until onset of tardive dyskinesia after initiation of risperidone or olanzapine was within one year. In eight reported cases of risperidone induced and three cases of olanzapine induced tardive dyskinesia, TD disappears either by stopping the drug or switching to other atypical antipsychotic drug. In seven cases of risperidone induced and three cases of olanzapine induced tardive dyskinesia, there was previous exposure to conventional antipsychotic drugs. It is concluded that induction of tardive dyskinesia by these medications is insufficiently documented in these reports but in some cases evidence is suggestive of the role of these drugs in development of tardive dyskinesia. There is no generally accepted treatment for tardive dyskinesia, thus long term studies with risperidone and olanzapine are needed in future to ascertain their tardive dyskinesia liability. Mental health professionals must remain vigilant about onset of tardive dyskinesia with these medications.
利培酮和奥氮平治疗精神科患者可引起多种迟发性运动障碍,给患者带来问题。这一临床问题需要精神卫生专业人员的紧急关注。因此,从 1996 年到 2004 年 8 月,对 Medline 和相关文献进行了全面研究。对已发表的 22 例利培酮(N=12)或奥氮平(N=10)引起的迟发性运动障碍病例进行了批判性回顾,并试图澄清与这些病例相关的各种问题。在这些报告中,大多数患者年龄较轻,女性,利培酮或奥氮平开始后迟发性运动障碍的发病间隔在一年以内。在 8 例利培酮引起的迟发性运动障碍和 3 例奥氮平引起的迟发性运动障碍中,停药或改用其他非典型抗精神病药物后 TD 消失。在 7 例利培酮引起的迟发性运动障碍和 3 例奥氮平引起的迟发性运动障碍中,之前曾接触过传统的抗精神病药物。结论是,这些报告中这些药物引起迟发性运动障碍的证据不足,但在某些情况下,有证据表明这些药物在迟发性运动障碍的发展中起作用。目前还没有公认的迟发性运动障碍治疗方法,因此未来需要对利培酮和奥氮平进行长期研究,以确定它们的迟发性运动障碍易感性。精神卫生专业人员必须对这些药物引起的迟发性运动障碍保持警惕。